Barclays PLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Barclays PLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 88.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,788 shares of the specialty pharmaceutical company's stock after buying an additional 51,005 shares during the period. Barclays PLC owned approximately 0.20% of Supernus Pharmaceuticals worth $3,393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC increased its position in shares of Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock valued at $273,000 after acquiring an additional 350 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after purchasing an additional 352 shares during the period. GAMMA Investing LLC increased its holdings in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 398 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock worth $741,000 after purchasing an additional 600 shares in the last quarter. Finally, Assetmark Inc. boosted its position in shares of Supernus Pharmaceuticals by 2.8% during the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company's stock worth $1,043,000 after buying an additional 908 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 0.0 %

SUPN stock traded up $0.01 during midday trading on Tuesday, hitting $35.60. The company's stock had a trading volume of 125,303 shares, compared to its average volume of 436,856. The firm has a 50-day simple moving average of $35.71 and a 200-day simple moving average of $32.34. The firm has a market capitalization of $1.97 billion, a P/E ratio of 33.27 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period last year, the business posted ($0.29) earnings per share. Supernus Pharmaceuticals's revenue was up 14.2% compared to the same quarter last year. On average, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares of the company's stock, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jack A. Khattar sold 125,000 shares of the firm's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares in the company, valued at $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.